Hematology

The Global Hematology Program seeks to advance and innovate the field of sickle cell disease, and other non-malignant childhood catastrophic blood disorders, through community building, tool design and implementation research, ultimately improving survival and outcomes worldwide.
 

The program’s vision is that of a world where every young person with sickle cell disease and other non-malignant catastrophic blood disorders receives specialized, compassionate care leading to a long and fulfilling life.

Sickle Cell Disease

Under-5 mortality among children with sickle cell disease remains alarmingly high, thus, sickle cell disease represents a growing public health crisis. However, the solutions are neither complex nor prohibitively expensive.  What is needed is global coordination and sustained political will toward a unifying target.  By investing in the widespread implementation of a low-cost, evidence-based essential care package, we can transform the health outcomes for the more than 500,000 children born with sickle cell disease each year, advancing equity and improving global child survival.

As scientific advances in sickle cell disease care and cure continue to accelerate, the opportunity to create a global initiative to design and implement scalable, sustainable, decentralized and integrated population-level approaches has never been more urgent or promising. 

The St. Jude Global Hematology Program joins the chorus calling for the community to speak with one voice. How we use our collective voice, and what message we communicate, matters more than ever. The time for action is now.  The world needs a global initiative for sickle cell disease, because every delay costs lives, lives we already have the tools to save.

Collaboration

ALUA – Lusophone Alliance of Specialists for Sickle Cell Disease

Lusophone Alliance of Specialists for Sickle Cell Disease (ALUA) is an organization that aims to promote technical and scientific knowledge to improve the diagnosis and treatment of people with sickle cell disease in the Community of Portuguese-speaking Countries (CPLP). ALUA’s mission is to increase the survival and quality of life of people with sickle cell disease, promoting strategic initiatives in diagnosis, treatment, epidemiology and training of health care providers.

The overall objective of ALUA is to promote collaboration between Portuguese-speaking countries for sickle cell disease care, involving governments, the CPLP and other health organizations at the local, regional and global levels. Cooperation health within the CPLP is one of the areas with the greatest potential for development and can contribute to responding to the enormous challenges faced by people living with sickle cell disease.

Scroll down to the bottom of the page to join the St. Jude Global Alliance Online Community and gain access to the ALUA Online Community group.

Contact

To learn more about the Global Hematology Program, email globalheme@stjude.org.